Higher GLP-1 costs lead to lower adherence
Semaglutides, or GLP-1s, can produce substantial weight loss if individuals adhere to their doctor's instructions. But a new study from the University of Georgia suggests patients aren't taking the weight loss medication as prescribed, often because of high out-of-pocket costs.
A new University of Georgia study reveals that high out-of-pocket costs for GLP-1 weight loss medications are significantly reducing patient adherence. Even at the lowest cost tier of $0–$21, three-quarters of patients stopped taking the medication within a year. However, when monthly out-of-pocket expenses exceeded $75, nonadherence rates soared above 80%.
Lead researcher Eunhae Shin attributes this trend to the financial barriers faced by patients, particularly those with employer-sponsored insurance that lacks price caps on GLP-1s. The study, published in JAMA Health Forum, found that adherence was lowest—around 17%—among patients paying more than $168 per month, a group that often includes individuals with high-deductible insurance plans.
While the study did not directly analyze socioeconomic factors, previous research indicates that low-income populations are more likely to enroll in plans with high cost-sharing and low premiums, leading to greater financial burdens on GLP-1 medications. Despite the short-term costs, Shin hopes future research will demonstrate long-term economic benefits, as effective weight loss medications could reduce healthcare costs by preventing chronic conditions and emergency room visits.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
